Trial reportNature medicine2009
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy.
Trial report in Nature medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01334684 (White Blood Cells Gene Expression Profiles as a Tool for Predicting Metformin Efficacy in Patients With Type 2 Diabetes Mellitus), which is not on this map. Cited by 130 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
White Blood Cells Gene Expression Profiles as a Tool for Predicting Metformin Efficacy in Patients With Type 2 Diabetes Mellitus
Who cites it
130 citing papers in PubMed.
- Circulating microRNAs as potential biomarkers of physical activity in geriatric patients with HCV.BMC molecular and cell biology · 2024Article
- Circulating microRNAs and hepcidin as predictors of iron homeostasis and anemia among school children: a biochemical and cross-sectional survey analysis.European journal of medical research · 2023Article
- The Effect of miRNA Gene Regulation on HIV Disease.Frontiers in genetics · 2022Review
- HCV and tumor-initiating stem-like cells.Frontiers in physiology · 2022Review
- Resilience in Long-Term Viral Infection: Genetic Determinants and Interactions.International journal of molecular sciences · 2021Article
- Review
- Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals.Hepatic medicine : evidence and research · 2021Article
- Making use of transcription factor enrichment to identify functional microRNA-regulons.Computational and structural biotechnology journal · 2021Article
- Expression Profiles of Exosomal MicroRNAs from HEV- and HCV-Infected Blood Donors and Patients: A Pilot Study.Viruses · 2020Article
- miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2.Oncology research · 2020Article
- The RNA-binding protein QKI-7 recruits the poly(A) polymerase GLD-2 for 3' adenylation and selective stabilization of microRNA-122.The Journal of biological chemistry · 2020Article
- Transcriptomic Analysis of mRNA-lncRNA-miRNA Interactions in Hepatocellular Carcinoma.Scientific reports · 2019Article
- Article
- Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir.Biomedical reports · 2019Article
- MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway.eLife · 2019Article
- Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5.Yonsei medical journal · 2018Article
- miRNAs regulate immune response and signaling during hepatitis C virus infection.European journal of medical research · 2018Review
- MiR-29c inhibits HCV replicationRSC advances · 2018Article
- Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.PloS one · 2018Article
- Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.OncoTargets and therapy · 2018Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several microRNAs (miRNAs), including liver-specific miR-122, have been implicated in the control of hepatitis C virus (HCV) RNA replication and its response to interferon (IFN) in human hepatoma cells. Our analysis of liver biopsies from subjects with chronic hepatitis C (CHC) undergoing IFN therapy revealed no correlation of miR-122 expression with viral load and markedly decreased pretreatment miR-122 levels in subjects who had no virological response during later IFN therapy; other investigated miRNAs showed only limited changes. These data have implications for the prospect of targeting miRNAs for CHC therapy.
Indexed as
Identifiers
19122656What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.